Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations

• Published in: Internal Medicine 2018/07/01, Vol.57(13), pp.1813-1817
• Main Authors: Miyata, Kazuaki, Ohno, Seiko, Itoh, Hideki, Horie, Minoru
• Format: Article
• Language: English
• Subjects: Adolescent; Bradycardia; Bradycardia - genetics; Cardiac arrhythmia; catecholaminergic polymorphic ventricular tachycardia; Child; Child, Preschool; Coronary artery disease; EKG; Electrocardiography; Female; Genetic Predisposition to Disease; Heart diseases; Hereditary diseases; Humans; Infant; Infant, Newborn; Internal medicine; Long QT syndrome; Male; Mutation; Original; Patients; Phenotype; Phenotypes; Physical exercise; Ryanodine Receptor Calcium Release Channel - genetics; Ryanodine receptors; RYR2 mutation; Tachycardia; Tachycardia, Ventricular - genetics; Ventricle
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.9843-17

Objective Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a lethal inherited disease characterized by ventricular arrhythmias induced by physical exercise or emotional stress. The major cause of CPVT is mutations in RYR2, which encodes the cardiac ryanodine receptor channel. Recent advances in sequencing technology have yielded incidental findings of RYR2 variants in other cardiac diseases. Analyzing the characteristics of RYR2 variants related to CPVT will be useful for differentiation from those related to other cardiac diseases. We examined the phenotypic characteristics of patients with RYR2 variants. Methods Seventy-nine probands carrying RYR2 variants whose diagnoses were either CPVT (n=68) or long QT syndrome (LQTS; n=11) were enrolled. We compared the characteristics of the electrocardiogram (ECG) and the location of the RYR2 mutations-N-terminal (NT), central region (CR) or C-terminal (CT)-between the two patient groups. Results Using the ECGs available from 53 probands before β-blocker therapies, we analyzed the heart rates (HRs). CPVT probands showed bradycardia more frequently (25/44; 57%) than LQTS probands (1/9; 11%; p=0.024). In CPVT patients, 20 mutations were located in NT, 25 in CR and 23 in CT. In LQTS patients, 5 mutations were located in NT, 2 in CR and 4 in CT. There were no significant differences in the locations of the RYR2 mutations between the phenotypes. Conclusion Bradycardia was highly correlated with the phenotype of CPVT. When a clinically-diagnosed LQTS patient with bradycardia carries an RYR2 mutation, we should be careful to avoid making a misdiagnosis, as the patient may actually have CPVT.